Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immunic Inc (IMUX)

Immunic Inc (IMUX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 151,339
  • Shares Outstanding, K 130,465
  • Annual Sales, $ 0 K
  • Annual Income, $ -97,170 K
  • EBIT $ -103 M
  • EBITDA $ -103 M
  • 60-Month Beta 1.46
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 340.55% (+10.58%)
  • Historical Volatility 113.75%
  • IV Percentile 63%
  • IV Rank 38.88%
  • IV High 773.64% on 10/21/25
  • IV Low 65.03% on 10/20/25
  • Expected Move (DTE 27) 0.3060 (27.82%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 132
  • Volume Avg (30-Day) 580
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 22,906
  • Open Int (30-Day) 21,785
  • Expected Range 0.7940 to 1.4060

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.10
  • Number of Estimates 6
  • High Estimate -0.05
  • Low Estimate -0.20
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8309 +32.39%
on 02/24/26
1.5100 -27.15%
on 03/12/26
+0.1600 (+17.02%)
since 02/20/26
3-Month
0.5062 +117.31%
on 12/30/25
1.5100 -27.15%
on 03/12/26
+0.5270 (+91.97%)
since 12/19/25
52-Week
0.5062 +117.31%
on 12/30/25
1.5100 -27.15%
on 03/12/26
-0.0400 (-3.51%)
since 03/20/25

Most Recent Stories

More News
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium

– Patent Covers Label-Mandated Dosing Scheme Across All Indications, Including Multiple Sclerosis; Previously Granted by the USPTO in 2023 –

IMUX : 1.1000 (-5.17%)
Immunic to Participate in Investor Conferences in March

NEW YORK , March 3, 2026 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and...

IMUX : 1.1000 (-5.17%)
Immunic: Q4 Earnings Snapshot

Immunic: Q4 Earnings Snapshot

IMUX : 1.1000 (-5.17%)
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

– Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 –

IMUX : 1.1000 (-5.17%)
Immunic Announces Closing of Oversubscribed Private Placement Financing

– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds –

IMUX : 1.1000 (-5.17%)
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds –

IMUX : 1.1000 (-5.17%)
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

– Additional CALLIPER MRI Analyses Show Reductions for Vidofludimus Calcium in Acute and Chronic Inflammatory Disease Activity –

IMUX : 1.1000 (-5.17%)
Immunic Highlights 2025 Accomplishments and Upcoming Milestones

– Completed Enrollment for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected by End of 2026 –

IMUX : 1.1000 (-5.17%)
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

NEW YORK , Nov. 26, 2025 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and...

IMUX : 1.1000 (-5.17%)
Immunic: Q3 Earnings Snapshot

Immunic: Q3 Earnings Snapshot

IMUX : 1.1000 (-5.17%)

Business Summary

Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis and psoriasis....

See More

Key Turning Points

3rd Resistance Point 1.2400
2nd Resistance Point 1.2000
1st Resistance Point 1.1500
Last Price 1.1000
1st Support Level 1.0600
2nd Support Level 1.0200
3rd Support Level 0.9700

See More

52-Week High 1.5100
Fibonacci 61.8% 1.1265
Last Price 1.1000
Fibonacci 50% 1.0081
Fibonacci 38.2% 0.8897
52-Week Low 0.5062

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.